NovaBridge Biosciences
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBP research report →
Range $9 – $9
Price Chart
About the company
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor.
- CEO
- Srishti Gupta
- IPO
- 2020
- Employees
- 30
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on NBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $95.67M
- P/E
- -2.05
- PEG
- -0.07
- P/S
- 0.00
- P/B
- 0.52
- EV/EBITDA
- 1.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1.43%
- ROIC
- -29.03%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-94,269,000
- Net Income
- $-46,269,000+71.5%
- EPS
- $-0.46+89.7%
- OCF Growth
- +94.6%
- FCF Growth
- +94.6%
- 52W High
- $5.19
- 52W Low
- $0.75
- 50D MA
- $1.26
- 200D MA
- $1.99
- Beta
- 1.71
- RSI (14)
- 31
- Avg Volume
- 507.09K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NovaBridge said it made meaningful first-half progress on givastomig and VIS-101, backed by a strong cash position and a flexible capital-allocation strategy.· August 20, 2026
- Cash and investments were about $216 million at June 30, 2026, with no debt, giving the company runway through multiple clinical milestones.
- Givastomig advanced toward registrational development, including FDA Fast Track designation and a potential accelerated approval path in first-line HER2-negative, CLDN18.2-positive, PD-L1-positive gastroesophageal cancer.
- Management highlighted public Phase Ib data for givastomig, including a 75% ORR at 8 mg/kg, tumor reduction in 51 of 52 evaluable patients, and preliminary median PFS of 16.9 months.
- VIS-101’s Phase IIa top-line data were described as positive, and the company is preparing to start a Phase IIb study in the second half of 2026.
- The new CEO emphasized a broader strategy of pairing BD, clinical development, and disciplined financing, including possible European partnerships and flexible structures for assets like Visara.
NovaBridge reported approximately $216 million in cash and investments as of June 30, 2026, including approximately $191 million in cash and cash equivalents and approximately $25 million in equity investment at fair value. Management said the company is debt-free and expects current resources to support the portfolio through key inflection points, including ESMO 2026 data for givastomig, completion of Phase II enrollment, a potential Phase III start as early as year-end 2026, and runway through the anticipated Phase III interim data readout in 2028. For givastomig, management cited publicly reported Phase Ib combination data at 8 mg/kg with a 75% ORR, tumor reduction in 51 of 52 evaluable patients, and preliminary median PFS of 16.9 months. No revenue, EPS, gross margin, or year-over-year financial comparisons were provided in this update.
Srishti Gupta framed NovaBridge as a company built to identify promising medicines and advance them efficiently through development, regulation, financing, and commercialization. She said the firm’s edge comes from combining business development, internal clinical development, and disciplined capital allocation, with the idea that different assets should follow different paths. Her tone was constructive and strategic, with repeated emphasis on early progress, optionality, and the belief that NovaBridge can bridge science to patient impact.
Kyler Lei focused on the balance sheet and funding runway, saying the company had approximately $216 million in cash and investments, including roughly $191 million in cash and cash equivalents and roughly $25 million in equity investment at fair value. He emphasized that the balance sheet is debt-free and provides financial flexibility to reach multiple clinical and strategic milestones. He also said current resources are expected to support givastomig through the anticipated Phase III interim data readout in 2028 and to fund continued VIS-101 development, including Phase IIb initiation/readout and planned Phase III work.
Analysts pressed management on where NovaBridge thinks it has an edge in Europe and how the company screens assets. Management said Europe is early-stage for them, but they see opportunities where differentiated assets can fit reimbursement systems, supported by their BD and clinical-development capabilities and partners’ commercial and market-access strengths. On screening, Gupta said the team increasingly rejects assets that lack a clear path to the next value inflection point or a convincing commercial pathway, especially if the label would not be differentiated. On Visara, management said the subsidiary may eventually need outside capital and could take multiple paths, including a stand-alone company or strategic partner, while NovaBridge wants maximum flexibility. On givastomig, Phil Dennis clarified FDA discussions were focused on the PD-L1-positive population and that PD-L1 <1% patients have not been discussed with FDA yet.
The call laid out a funded clinical story: NovaBridge has cash, no debt, and several near-term catalysts across two lead programs. Management sounded optimistic that givastomig’s regulatory feedback, Fast Track status, and broad early activity support a credible path toward registrational development, while VIS-101 showed positive early efficacy and safety and is moving into Phase IIb.
The company is still early and has no commercial products, so execution risk remains high across development, financing, and partnering. Givastomig’s encouraging data are still single-arm and need randomized confirmation, while the Phase III start is only targeted for as early as the fourth quarter of 2026 and is subject to ongoing planning and financing activities. Visara may also require future dilution or outside capital, and management acknowledged that many of the European and women’s health growth ideas are still in early exploration.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.8%
- Shares Outstanding
- 50.12M
- Float Shares
- 41.97M
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 15 ETFs
Biggest fund positions in NBP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Hagler Mark Arnold | buy | 184,000 |
| Nov 17, 26 | Hagler Mark Arnold | buy | 46,000 |
| Nov 2, 26 | Silberstein Charles | other | 0 |
| Oct 15, 26 | Woo Ian Ying | other | 13,271 |
| Oct 15, 26 | Woo Ian Ying | other | 5,770 |
| Sep 17, 26 | Dennis Phillip Andrew | other | 23,695 |
| Sep 18, 26 | Dennis Phillip Andrew | sell | 8,209 |
| Sep 17, 26 | Dennis Phillip Andrew | other | 10,302 |
| Sep 9, 26 | Cao Sean Wuxiong | sell | 107,978 |
| Sep 8, 26 | Dewhurst Martin William | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NBP coverage
Recent articles, reports, and earnings notes.
No research on NBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBP report →Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD
globenewswire.com · Nov 18
NovaBridge Biosciences to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 9
NovaBridge Biosciences (NBP) Discusses Mature Givastomig Data and Registrational Development Strategy Transcript
seekingalpha.com · Nov 2
NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
globenewswire.com · Oct 28
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
globenewswire.com · Oct 25
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
globenewswire.com · Oct 20
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
prnewswire.com · Oct 13
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
globenewswire.com · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.